Literature DB >> 19255193

Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide.

Ying-Jie Lu1, Sophie Forte, Claudette M Thompson, Porter W Anderson, Richard Malley.   

Abstract

Cell wall polysaccharide (CWPS), pneumolysin, and surface adhesin A (PsaA) are antigens common to virtually all serotypes of Streptococcus pneumoniae (pneumococcus), and all have been studied separately for use in protection. Previously we showed that protection against nasopharyngeal (NP) colonization by intranasal vaccination of mice with killed pneumococci is mediated by T(H)17 cells and correlates with interleukin-17A (IL-17A) expression by T cells in vitro; we have also shown that CWPS and other species-common antigens protect against colonization by a similar mechanism. Here we made a fusion protein of PsaA with the pneumolysin nontoxic derivative PdT and then coupled CWPS to the fusion protein, aiming to enhance immune responses to all three antigens. When given intranasally with cholera toxin adjuvant, the fusion conjugate induced higher serum antibody titers and greater priming for IL-17A responses than an equimolar mixture of the three antigens. The conjugate administered intranasally protected mice against experimental NP colonization by a strain of serotype 6B, while mice immunized with the mixture or with bivalent conjugates were not protected. Subcutaneous immunization with the conjugate and alum adjuvant likewise induced higher antibody titers than the mixture, primed for IL-17A responses, and reduced colonization. The conjugate, but not the antigen mixture, fully protected mice from fatal pneumonia caused by a highly virulent serotype 3 strain. Thus, a covalent construct of three antigens common to all serotypes exhibits protection with both mucosal and systemic administration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255193      PMCID: PMC2681726          DOI: 10.1128/IAI.01554-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  The determination of sugar in blood and spinal fluid with anthrone reagent.

Authors:  J H ROE
Journal:  J Biol Chem       Date:  1955-01       Impact factor: 5.157

2.  Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci.

Authors:  S C Szu; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

3.  Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents.

Authors:  A Lees; B L Nelson; J J Mond
Journal:  Vaccine       Date:  1996-02       Impact factor: 3.641

Review 4.  Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease.

Authors:  G R Siber; C Thompson; G R Reid; J Almeido-Hill; B Zacher; M Wolff; M Santosham
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

5.  Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae.

Authors:  A M Berry; J E Alexander; T J Mitchell; P W Andrew; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

6.  Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody.

Authors:  J Yother; C Forman; B M Gray; D E Briles
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

7.  Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae.

Authors:  H Y Wu; M H Nahm; Y Guo; M W Russell; D E Briles
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

8.  Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae.

Authors:  J E Alexander; R A Lock; C C Peeters; J T Poolman; P W Andrew; T J Mitchell; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

9.  Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae.

Authors:  D E Briles; M Nahm; K Schroer; J Davie; P Baker; J Kearney; R Barletta
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

10.  Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA).

Authors:  D F Talkington; B G Brown; J A Tharpe; A Koenig; H Russell
Journal:  Microb Pathog       Date:  1996-07       Impact factor: 3.738

View more
  30 in total

1.  Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax.

Authors:  Sandip K Datta; Mojgan Sabet; Kim Phung L Nguyen; Patricia A Valdez; Jose M Gonzalez-Navajas; Shamima Islam; Ivan Mihajlov; Joshua Fierer; Paul A Insel; Nicholas J Webster; Donald G Guiney; Eyal Raz
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

Review 2.  Th17 cytokines and vaccine-induced immunity.

Authors:  Yinyao Lin; Samantha R Slight; Shabaana A Khader
Journal:  Semin Immunopathol       Date:  2010-01-30       Impact factor: 9.623

Review 3.  Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity.

Authors:  Richard Malley; Porter W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-02       Impact factor: 11.205

Review 4.  The host immune dynamics of pneumococcal colonization: implications for novel vaccine development.

Authors:  M Nadeem Khan; Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Immunization with a ZmpB-based protein vaccine could protect against pneumococcal diseases in mice.

Authors:  Yi Gong; Wenchun Xu; Yali Cui; Xuemei Zhang; Run Yao; Dairong Li; Hong Wang; Yujuan He; Ju Cao; Yibing Yin
Journal:  Infect Immun       Date:  2010-11-22       Impact factor: 3.441

6.  Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine.

Authors:  Shifeng Wang; Yuhua Li; Huoying Shi; Giorgio Scarpellini; Ascencion Torres-Escobar; Kenneth L Roland; Roy Curtiss
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

7.  Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.

Authors:  Jianghong Xu; Wenjia Dai; Zhengmin Wang; Bing Chen; Zhongming Li; Xiaoyong Fan
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

8.  Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide.

Authors:  Ying-Jie Lu; Ian Chr Skovsted; Claudette M Thompson; Porter W Anderson; Richard Malley
Journal:  Microb Pathog       Date:  2009-07-03       Impact factor: 3.738

Review 9.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

Review 10.  Potential role for mucosally active vaccines against pneumococcal pneumonia.

Authors:  Kondwani C Jambo; Enoch Sepako; Robert S Heyderman; Stephen B Gordon
Journal:  Trends Microbiol       Date:  2009-12-22       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.